Seastar Medical Holding Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Seastar Medical Holding Corp is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
Seastar Medical Holding Corp valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Seastar Medical has little or no product revenue yet. It passes 2 of our 3 financial-health checks.
Our model value for Seastar Medical Holding is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 87 health care equipment companies we cover. Where it lags: change in growth rate of -111.9pp ranks 129 of 129 health care equipment companies we cover.
Current signal Revenue growth decelerating: TTM revenue growth slowed to 123.6% (-111.9pp vs the prior quarter), the 3rd consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Seastar Medical Holding Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.4 ~$0.5–$1.9 | Left out: out of range vs price (0.18x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Seastar Medical Holding Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share price | $110.75 | $19.40 | $2.40 |
| Market value | $96m | $73m | $5m |
| + Net debt (− = net cash) | $9m | −$671000 | $0 |
| Enterprise value | $105m | $72m | $5m |
| Multiples | |||
| Price / sales | — | n/m | 4.0x |
| Price / earnings | — | — | — |
| Price / free cash flow | — | — | — |
| EV / EBITDA | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$3.66 | +38% | $2m | +62% |
| Next | −$2.33 | +36% | $3m | +47% |
The consensus EPS forecast for the current fiscal year is +0.5% on 90 days ago. In the last 30 days, 0 analysts raised Seastar Medical Holding Corp's forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.64 | −$2.33 |
| 60 days ago | −$3.66 | −$2.33 |
| 30 days ago | −$3.66 | −$2.33 |
| 7 days ago | −$3.66 | −$2.33 |
| Now | −$3.66 | −$2.33 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.97 | −$0.91 | +6.2% |
| Mar 2026 | −$0.82 | −$0.90 | −9.1% |
| Dec 2025 | −$1.01 | −$0.80 | +21.2% |
| Sept 2025 | −$1.50 | −$1.30 | +13.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| ICU | −59% | −89% | −83% | −88% | −9% |
| Industry peers (median) | −37% | −8% | −19% | −16% | −15% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| ICU | 58% | 33% | 17% | 25% | 36% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| ICU | −68% | −97% | −95% | −91% | −57% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since March 18, 2021: 100% from October 28, 2022 to November 2, 2026. Getting back needed a 140882% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 12, 2026 | −14.1% | +0.9% | −11.4% | −17.9% |
| May 13, 2026 | −13.2% | +1.4% | −18.0% | −38.4% |
| March 25, 2026 | +24.6% | −1.2% | +58.9% | +84.4% |
| November 13, 2025 | −23.8% | −1.7% | −37.9% | −37.9% |
| May 14, 2025 | −2.4% | +0.6% | +2.4% | −7.1% |
| March 27, 2025 | −30.0% | −2.3% | −42.8% | −47.7% |
| November 13, 2024 | −26.6% | −0.6% | −19.5% | −25.5% |
| May 14, 2024 | −12.5% | +1.7% | +3.8% | −63.9% |
| April 17, 2024 | −23.9% | −0.8% | −28.5% | −43.4% |
| November 22, 2023 | −12.3% | +0.4% | +20.3% | +5.9% |
| August 15, 2023 | −14.4% | −1.9% | −23.8% | −34.0% |
| May 16, 2023 | −32.9% | +0.5% | −30.9% | −44.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY24 Q2 | $0 |
| FY24 Q3 | $68K |
| FY24 Q4 | $135K |
| FY25 Q1 | $428K |
| FY25 Q2 | $766K |
| FY25 Q3 | $881K |
| FY25 Q4 | $1.2M |
| FY26 Q1 | $1.4M |
| FY26 Q2 | $1.7M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY25 Q3 | 1195.6% |
| FY25 Q4 | 814.1% |
| FY26 Q1 | 235.5% |
| FY26 Q2 | 123.6% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY24 Q3 | -23547.1% |
| FY24 Q4 | -13216.3% |
| FY25 Q1 | -4138.8% |
| FY25 Q2 | -1932.2% |
| FY25 Q3 | -1580.5% |
| FY25 Q4 | -986.5% |
| FY26 Q1 | -832.5% |
| FY26 Q2 | -816.6% |
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 0 | 0 | 1 | 2 |
| Gross profit | 0 | 0 | 1 | 2 |
| Operating income | −14 | −18 | −12 | −14 |
| Net income | −26 | −25 | −12 | −14 |
| Diluted EPS | −$30.26 | −$6.63 | — | — |
| Growth (year on year) | ||||
| Revenue | — | — | +814.1% | +123.6% |
| Margins | ||||
| Gross margin | — | 100.0% | 95.7% | 92.6% |
| Operating margin | — | <−999% | −986.6% | −816.6% |
| Net margin | — | <−999% | −984.6% | −795.5% |
| Cash flow | ||||
| Cash from operations | −10 | −16 | −14 | −14 |
| Stock-based pay | 2 | 1 | 1 | 0 |
| Balance sheet | ||||
| Cash | 0 | 2 | — | — |
| Total debt | 9 | 1 | 1 | 0 |
| Net debt (negative = net cash) | 9 | −1 | — | — |
| Diluted shares | — | 4m | 2m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 68 | 67 | 293 | 338 | 183 | 420 | 495 | 615 |
| Gross profit | 68 | 67 | 293 | 311 | 169 | 408 | 449 | 561 |
| Operating income | −4,456 | −4,767 | −3,822 | −1,756 | −3,579 | −3,016 | −3,603 | −3,791 |
| Net income | −4,478 | −4,419 | −3,772 | −2,002 | −3,472 | −2,904 | −3,521 | −3,730 |
| Diluted EPS | −$11.00 | −$0.53 | −$4.40 | −$1.80 | — | — | — | — |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | — | +169.1% | +526.9% | +68.9% | +82.0% |
| Margins | ||||||||
| Gross margin | 100.0% | 100.0% | 100.0% | 92.0% | 92.3% | 97.1% | 90.7% | 91.2% |
| Operating margin | <−999% | <−999% | <−999% | −519.5% | <−999% | −718.1% | −727.9% | −616.4% |
| Net margin | <−999% | <−999% | <−999% | −592.3% | <−999% | −691.4% | −711.3% | −606.5% |
| Cash flow | ||||||||
| Cash from operations | −5,002 | −4,693 | −2,654 | −3,007 | −3,844 | −4,094 | −2,761 | −2,994 |
| Stock-based pay | 200 | 212 | 167 | 97 | 290 | 70 | 91 | −99 |
| Last 12 months unless stated | ICU | IMDX | FEMY | VNRX | PLSE | ICCM | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $2m | $2m | $2m | $2m | $1m | $3m | $99m |
| Revenue growth, last 12 months | 123.6% | −60.8% | 21.9% | 86.3% | 100.0% | 2.7% | 9.2% |
| Revenue growth, 3-year average | — | 14.9% | 24.3% | 68.0% | — | — | 13.5% |
| Revenue growth, latest quarter | 82.0% | −53.9% | −18.9% | −2.0% | 100.0% | — | 10.2% |
| Gross margin | 92.6% | 48.3% | 60.9% | — | 0.3% | 36.3% | 61.2% |
| Operating margin | −816.6% | <−999% | −763.9% | −790.2% | <−999% | −446.7% | −8.5% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | >999% | — | −17.9% |
| Net margin | −795.5% | <−999% | −511.8% | <−999% | <−999% | −445.6% | −12.0% |
| Cash from operations / revenue | −799.4% | <−999% | −767.6% | −795.9% | <−999% | −431.3% | −1.9% |
| Free-cash-flow margin | — | <−999% | −786.0% | −796.7% | <−999% | −432.4% | −3.9% |
| Free-cash-flow margin, 3-year average | — | <−999% | <−999% | <−999% | >999% | — | −7.0% |
| Stock pay / revenue | 20.5% | 150.8% | 26.2% | 38.2% | >999% | 40.6% | 6.1% |
| Change in share count | — | 16.8% | — | 16.3% | 7.4% | 25.0% | 4.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 123.6% | 9.1% | 4 of 129 |
| Change in growth rate Growth | -111.9pp | -0.6pp | 129 of 129 |
| Gross margin Profitability | 92.6% | 61.9% | 4 of 123 |
| Operating margin Profitability | -816.6% | -8.3% | 120 of 132 |
| Net margin Profitability | -795.5% | -12.0% | 120 of 133 |
| Stock pay as % of revenue Cash generation | 20.5% | 6.1% | 99 of 123 |
| Long-term debt as % of assets Balance sheet | 0.0% | 24.2% | 1 of 87 |
| Days sales outstanding Balance sheet | 44 days | 57 days | 29 of 118 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Geode Capital Management, LLC | $182,010 | 50K | 31.3% | ▼ 10.9% |
| Vanguard Capital Management LLC | $121,444 | 33K | 20.9% | ▲ 14.9% |
| UBS Group AG | $115,231 | 31K | 19.8% | ▲ 3859.4% |
| Vanguard Fiduciary Trust Co | $50,250 | 14K | 8.6% | 0.0% |
| Jane Street Group, LLC | $46,367 | 13K | 8.0% | ▼ 54.8% |
| Northern Trust Corp | $38,175 | 10K | 6.6% | New |
| PNC Financial Services Group, Inc. | $18,141 | 5K | 3.1% | ▲ 182.8% |
| Tower Research Capital LLC (TRC) | $4,977 | 1K | 0.9% | ▼ 2.8% |
| Blackrock, Inc. | $3,351 | 1K | 0.6% | 0.0% |
| Osaic Holdings, Inc. | $714 | 0K | 0.1% | ▼ 15.2% |
| Newedge Advisors, LLC | $647 | 0K | 0.1% | 0.0% |
| Vanguard Global Advisers, LLC | $606 | 0K | 0.1% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Seastar Medical Holding Corp's complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Messinger Michael Chief Financial Officer | August 18, 2026 | Buy | 750 | $3.27 | $2,452 |
| Baird Jennifer A Director | December 19, 2025 | Buy | 4,200 | $0.24 | $1,008 |
| Messinger Michael Chief Financial Officer | December 9, 2025 | Buy | 14,500 | $0.35 | $5,075 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
